Metsera Stock (MTSR) Skyrockets Over 50% as Pfizer Nears Massive $7.3 Billion Takeover Deal

Pharma giant Pfizer drops a bombshell acquisition bid—sending Metsera shares into orbit with a stunning 50% surge.

The $7.3 Billion Power Play

Pfizer's nearing a blockbuster takeover, valuing the biotech firm at a cool $7.3 billion. Markets react instantly—MTSR bulls pile in, shorts get crushed.

Deal Dynamics Driving the Frenzy

Speculation runs wild that Pfizer's betting big on Metsera's pipeline. No official confirmation yet, but Wall Street's already pricing in the premium.

Another day, another mega-deal—because nothing says 'value creation' like two pharma giants merging while drug prices keep climbing.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Pfizer Close to Acquiring Metsera in Weight-Loss Drug Market Push

As part of the potential deal, Pfizer will pay Metsera $47.50 in cash and an additional $22.50 contingent upon the achievement of certain performance milestones, bringing the total value of the deal to up to $7.3 billion. The deal price represents a 42.5% premium compared to Metsera stock’s closing price of $33.32 on Friday.

This deal reflects Pfizer’s interest in the attractive anti-obesity drug market after its own experimental weight-loss pill, danuglipron, disappointed in clinical trials this year. Meanwhile, the company continues to bolster its business through strategic acquisitions. In 2023, Pfizer acquired oncology-focused biotech Seagen for $43 billion.

Metsera, which went public this year, is working on weight-loss treatments that could improve upon existing weekly anti-obesity injections (known as GLP-1s): Eli Lilly’s (LLY) Zepbound and Novo Nordisk’s (NVO) Wegovy, which have certain side effects such as muscle loss. Both Eli Lilly and Novo Nordisk have recently released clinical data for their weight-loss pills.

It is worth noting that Metsera’s lead candidate, MET-097i, an injectable, showed an average weight loss of 11.3% in patients during a Phase 2 trial.

Is MTSR Stock a Buy?

Wall Street has a Strong Buy consensus rating on Metsera stock based on four unanimous Buys. The average MTSR stock price target of $63.50 indicates 90.6% upside potential.

Is PFE stock a Buy, Sell, or Hold?

Currently, Wall Street is sidelined on Pfizer stock based on 12 Holds and three Buys. The average PFE stock price target of $28.08 indicates about 17% upside potential from current levels.